Tuesday, 8 April 2014

BUSULFEX (busulfan) 6 mg/mL injection - potential for particulate matter in 10 mL vials

Otsuka Canada Pharmaceutical Inc. in consultation with Health Canada would like to inform you of a potential risk of black particulate matter in vials of BUSULFEX® (busulfan) 6 mg/mL Injection. BUSULFEX® (busulfan) Injection is indicated for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation, including: acute lymphocytic leukemia, acute non-lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease, multiple myeloma, and myelodysplastic syndrome. Read more here.

No comments:

Post a Comment